HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Profile: Avience Biomedicals
Jun-16-2026

Avience Biomedicals was incorporated as Avience Biomedicals Private Limited in December 23, 2019, in Delhi. Subsequently, the company was converted into a Public Limited Company pursuant to shareholders resolution passed at the Extra Ordinary General Meeting of the company held on June 26, 2024 and the name of the company was changed from ‘Avience Biomedicals Private Limited’ to ‘Avience Biomedicals Limited’ on September 03,2024.

The company is a medical consumable company dedicated to manufacturing of Vitro-Diagnostic (IVD) products and medical devices. The company commenced its journey by producing essential diagnostic kits like Viral Transport Media (VTM), Covid, Human Immunodeficiency Viruses (HIV), HBs AG, Malaria, Dengue and others aimed at aiding medical institutions with affordable and good-quality solutions. The company has expanded its product range from IVD rapid test kits to include a comprehensive line of medical devices such as Serology products, Biochemistry Analyser and Biochemistry Reagents, showcasing a dedication to addressing various healthcare needs. 

Being majorly into B2B and B2C market, its products cater to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide as well as overseas. In addition to manufacturing, the company also act as distributors and traders of medical equipment. The company is an ISO 9001:2016, ISO 13485, ZED MSME Gold and Good Manufacturing Practice (GMP) certified organization.

Business area of the company 

The company is primarily engaged in the business of manufacturing and selling of medical consumables. Its diversified product portfolio can primarily be divided into two main categories -- Manufacturing of Medical Consumables and Distribution of branded equipment.

Products of the company

Reagents & Consumable

  • Biochemistry Reagents - for liver function tests (LFT), kidney function tests (KFT), lipid profiles, glucose tests, etc.
  • Haematology Reagents - for complete blood count (CBC), differential count, etc.
  • Immunoassay Reagents - for detecting hormones, infectious diseases, and tumour markers.
  • Consumables - cuvettes, pipette tips, test tubes, microplates, and filters.

Diagnostic Instruments & Equipment

  • Automated Biochemistry Analysers - fully or semi-automated systems.
  • Haematology Analysers - 3-part or 5-part differential systems.
  • Immunoassay Analysers - CLIA systems, ELISA readers and washers.
  • Molecular Diagnostic Instruments - PCR machines, thermocyclers.
  • Microbiology Instruments - incubators, autoclaves, colony counters.
  • Electrolyte Analyser - used to measure the concentration of electrolytes in biological fluids such as blood, serum, plasma, or urine.

History and milestones

  • 2020-21: Inauguration of Noida Factory.
  • 2020-21: Initiated E-Commerce Sales through Government e-Marketplace (GeM) OEM.
  • 2021-22: Tenfold increase in turnover during FY 2021-22.
  • 2021-22: The company obtained 4 manufacturing licenses.
  • 2022-23: The company received approval for 10 additional production licenses.
  • 2023-24: The company secured an allotment of commercial land measuring 2,100 square meters within the Medical Device Park, located in the Yamuna Expressway Industrial Development Area, at a nominal lease rate.
  • 2023-24: The company dispatched first export order.
  • 2023-24: The company successfully completed first export order to Somalia and entered the African continent.
  • 2023-24: The company received approval from the Ethiopian Food and Drug Authority (EFDA) to export its products.
  • 2023-24: The company received a large government supply order after winning a bid in Andhra Pradesh for Rs 82.05 lakh.
  • 2023-24: The WHO recognized the company’s manufacturing process as a Good Manufacturing Practice (GMP) for producing quality products that meet international quality standards.
  • 2023-24: The company secured MSME ZED Gold Certification.
  • 2023-24: The company received approval for 31 new production licenses.
  • 2024-25: The company laid foundation stone for the new large production facility at the Medical Device Park at Yamuna Expressway Industrial Development Area. 
  • 2024-25: The company became one of the few manufacturers in India to receive validation for the sickle cell test from ICMR.
  • 2024-25: The company obtained its first license for manufacturing hematology equipment in FY 2024-25.
  • 2024-25: The company transitioned to a public company, marking a significant milestone in its growth and expansion.
  • 2024-25: The company received approval for 32 new production licenses.
  • 2025-26: The company received approval for 11 new production licenses.
  • 2026-27: The company received approval for 10 new production licenses.

  RELATED NEWS >>